heart failure with preserved ejection fraction Archives

Emerging concepts in heart failure treatment and management: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction

Andrea Beatriz De Lorenzi, Edgardo Kaplinsky, Marx Rivera Zambrano, Laia Tomás Chaume, Joan Monell Rosas

Article Type

Review

Published

04 Jan 2023

This article provides an overview of the main pathophysiological characteristics of heart failure with preserved ejection fraction (HFpEF), the considered diverse biological effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in this context and the supporting clinical evidence of SGLT2i in patients with HFpEF with a focus on the EMPEROR-Preserved and DELIVER trials.